Quest for the right Drug
פמטרקסד תרו 500 מ"ג PEMETREXED TARO 500 MG (PEMETREXED)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
תוך-ורידי : I.V
צורת מינון:
אבקה להכנת תמיסה מרוכזת לעירוי : POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
4.8 Undesirable effects Summary of the safety profile The most commonly reported undesirable effects related to pemetrexed, whether used as monotherapy or in combination, are bone marrow suppression manifested as anaemia, neutropenia, leukopenia, thrombocytopenia and gastrointestinal toxicities, manifested as anorexia, nausea, vomiting, diarrhoea, constipation, pharyngitis, mucositis, and stomatitis. Other undesirable effects include renal toxicities, increased aminotransferases, alopecia, fatigue, dehydration, rash, infection/sepsis and neuropathy. Rarely seen events include Stevens-Johnson syndrome and toxic epidermal necrolysis. Tabulated list of adverse reactions The table 4 lists the adverse drug events regardless of causality associated with pemetrexed used either as a monotherapy treatment or in combination with cisplatin from the pivotal registration studies (JMCH, JMEI, JMBD, JMEN and PARAMOUNT) and from the post marketing period. ADRs are listed by MedDRA body system organ class. The following convention has been used for classification of frequency: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1000 to < 1/100); rare (≥ 1/10,000 to < 1/1000); very rare (< 1/10,000) and not known (cannot be estimated from available data). Table 4 - Frequencies of all grades adverse drug events regardless of causality from the pivotal registration studies: JMEI (pemetrexed vs docetaxel), JMDB (pemetrexed and cisplatin versus GEMZAR and cisplatin, JMCH (pemetrexed plus cisplatin versus cisplatin), JMEN and PARAMOUNT (pemetrexed plus Best Supportive Care versus Placebo plus Best Supportive Care) and from post-marketing period. System Very Common Uncommo Rare Very rare Not Organ common n known Class (MedDRA) Infections and Infectiona Sepsisb Dermo- infestations Pharyngitis hypodermitis Blood and Neutropenia Febrile Pancytopenia Autoimmune lymphatic Leukopenia neutropenia haemolytic system Haemoglobin Platelet count anaemia disorders decreased decreased Immune Hypersensiti- Anaphylac- System vity tic shock disorders System Very Common Uncommo Rare Very rare Not Organ common n known Class (MedDRA) Metabolism Dehydration and nutrition disorders Nervous Taste disorder Cerebrovasc system Peripheral ular accident disorders motor Ischaemic neuropathy stroke Peripheral Haemorrhag sensory e intracranial neuropathy Dizziness Eye disorders Conjunctivitis Dry eye Lacrimation increased Keratoconjunc tivitis sicca Eyelid oedema Ocular surface disease Cardiac Cardiac failure Angina disorders Arrhythmia Myocardial infarction Coronary artery disease Arrhythmia supraventric ular Vascular Peripheral disorders ischaemiac Respiratory, Pulmonary thoracic and embolism mediastinal Interstitial disorders pneumonitisb d Gastrointes- Stomatitis Dyspepsia Rectal tinal Anorexia Constipation haemorrhage disorders Vomiting Abdominal Gastrointesti Diarrhoea pain nal Nausea haemorrhage Intestinal perforation Oesophagitis Colitise Hepatobiliary Alanine Hepatitis disorders aminotransfera se increased Aspartate aminotransfera se increased System Very Common Uncommo Rare Very rare Not Organ common n known Class (MedDRA) Skin and Rash Hyperpigment Erythema Stevens- subcutaneous Skin ation Johnson tissue exfoliation Pruritus syndromeb disorders Erythema Toxic multiforme epidermal Alopecia necrolysisb Urticaria Pemphigoid Dermatitis bullous Acquired epidermolysi s bullosa Erythema- tous oedemaf Pseudocellu- litis Dermatitis Eczema Prurigo Renal and Creatinine Renal failure Nephroge- urinary clearance Glomerular nic diabetes disorders decreased filtration rate insipidus Blood decreased Renal creatinine tubular increasede necrosis General Fatigue Pyrexia disorders and Pain administratio Oedema n site Chest pain conditions Mucosal inflammation Investigations Gamma- glutamyltransf erase increased Injury, Radiation Recall poisoning and oesophagitis pheno- procedural Radiation menon complications pneumonitis a with and without neutropenia b in some cases fatal c sometimes leading to extremity necrosis d with respiratory insufficiency e seen only in combination with cisplatin f mainly of the lower limbs Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form via the following link: https://sideeffects.health.gov.il/
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
לא צוין
הגבלות
לא צוין
מידע נוסף